Pharmaceuticals 10 December 2025 - 14 December 2025

Eli Lilly shares closed at $1,027.51, up 1.8% Friday, and traded near $1,028–$1,029 after hours following a European regulatory panel’s recommendation to expand Mounjaro use to children 10 and older with type 2 diabetes. Volume was about 3.2 million shares. The stock remains 7.6% below its 52-week high set in late November.

Eli Lilly shares traded near $1,009 Friday after its obesity drug retatrutide showed 28.7% average weight loss in a Phase 3 trial, though with notable discontinuation rates. Reuters reported FDA leaders pushed to speed review of Lilly’s oral GLP-1 drug orforglipron, raising internal concerns. The company is building a $6 billion Alabama plant to boost manufacturing. Analyst price targets remain supportive but vary widely.

Eli Lilly became the first pharmaceutical company to surpass a $1 trillion market value on November 21, 2025, driven by strong demand for its obesity and diabetes drugs. By December 11, shares traded near $993, with a market cap of about $890 billion, down from the peak. The company’s stock is up over 550% in five years, far outpacing the S&P 500. Investors are now focused on valuation rather than growth.